US equities |
SPCX $166.98 ▲+5.04% NVDA $237.16 ▲+1.37% MU $1,065.37 ▼-0.89% TSLA $377.27 ▲+1.80% MSFT $525.38 ▲+1.52% INTC $116.51 ▼-2.36% SNDK $1,713.53 ▼-0.38% META $745.64 ▲+2.41%
FinancialContent

Articles published by Alzamend Neuro

News headline image
Alzamend Neuro Issues Letter to Stockholders
From Alzamend Neuro
Via Business Wire
Tickers ALZN
News headline image
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
From Alzamend Neuro
Via Business Wire
Tickers ALZN
News headline image
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
From Alzamend Neuro
Via Business Wire
Tickers ALZN
News headline image
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
From Alzamend Neuro
Via Business Wire
Tickers ALZN
News headline image
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference
From Alzamend Neuro
Via Business Wire
Tickers ALZN
News headline image
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s
From Alzamend Neuro
Via Business Wire
Tickers ALZN
News headline image
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
From Alzamend Neuro
Via Business Wire
Tickers ALZN
News headline image
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease
From Alzamend Neuro
Via Business Wire
Tickers ALZN